• Search
  • Advanced Search

Review

March 9, 2023


Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka
Clin Mol Hepatol. 2023;29(4):851-868.

The current requirement for biomarkers to detect hepatitis B virus (HBV) infection is polarized. One is a fully-automated and highly sensitive measurement system; the other is a simple system for...

Review

March 14, 2023


Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(4):869-890.

Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set...

Review

April 13, 2023


Hepatorenal syndrome: Current concepts and future perspectives
Chan-Young Jung, Jai Won Chang
Clin Mol Hepatol. 2023;29(4):891-908.

Hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function, remains a major complication in patients with advanced cirrhosis, often leading to death before liver transplantation (LT). Recent...

Review

May 25, 2023


The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clin Mol Hepatol. 2023;29(4):909-923.
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the...

Review

June 5, 2023


Evidence-based hyponatremia management in liver disease
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clin Mol Hepatol. 2023;29(4):924-944.

Hyponatremia is primarily a water balance disorder associated with high morbidity and mortality. The pathophysiological mechanisms behind hyponatremia are multifactorial, and diagnosing and treating this disorder remains challenging. In this...

Review

August 14, 2023


Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma
Hwa Kyung Byun, Changhwan Kim, Jinsil Seong
Clin Mol Hepatol. 2023;29(4):945-957.

Hepatocellular carcinoma (HCC) is a highly lethal cancer with limited treatment options and poor prognosis. Carbon ion radiotherapy (CIRT) has emerged as a promising treatment modality for HCC due to...

Review

August 29, 2023


Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma
Sung Uk Lee, Tae Hyun Kim
Clin Mol Hepatol. 2023;29(4):958-968.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, and external beam radiation therapy has emerged as a promising approach for managing HCC. Proton beam therapy (PBT) offers dosimetric...

Original Article

July 5, 2023


Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, et al.
Clin Mol Hepatol. 2023;29(4):987-1001.

Background/Aims: To investigate whether non-alcoholic fatty liver disease (NAFLD) in individuals without generalized obesity is associated with visceral fat obesity (VFO), sarcopenia, and/or myosteatosis. Methods: This cross-sectional analysis included 14,400 individuals...

Original Article

September 11, 2023


Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study
Vy H. Nguyen, Isaac Le, Audrey Ha, et al.
Clin Mol Hepatol. 2023;29(4):1002-1012.

Background/Aims: Understanding of nonalcoholic fatty liver disease (NAFLD) continues to expand, but the relationship between race and ethnicity and NAFLD outside the use of cross-sectional data is lacking. Using longitudinal...

Original Article

July 5, 2023


Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
Ha Il Kim, Jihyun An, Seungbong Han, et al.
Clin Mol Hepatol. 2023;29(4):1013-1028.

Background/Aims: There is no clear consensus on the relative ranking of interventional and radiation techniques with indications similar to those of radiofrequency ablation (RFA) for the treatment of early hepatocellular...

Original Article

August 29, 2023


Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection
Jeongin Yoo, Heejin Cho, Dong Ho Lee, et al.
Clin Mol Hepatol. 2023;29(4):1029-1042.

Background/Aims: The prediction of clinical outcomes in patients with chronic hepatitis B (CHB) is paramount for effective management. This study aimed to evaluate the prognostic value of computed tomography (CT)...
Current Issue
Volume 29(4); Oct 2023
Special Review
1849
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clin Mol Hepatol. 2023;29(4):831-843.   Published online August 25, 2023
View: 1881   Download: 239  Citations: 3
1854
Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(4):844-850.   Published online September 6, 2023
View: 1040   Download: 129
Review
1791
Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka
Clin Mol Hepatol. 2023;29(4):851-868.   Published online March 9, 2023
View: 5460   Download: 286  Citation: 1
1798
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(4):869-890.   Published online March 14, 2023
View: 1757   Download: 141  Citations: 3
1816
Hepatorenal syndrome: Current concepts and future perspectives
Chan-Young Jung, Jai Won Chang
Clin Mol Hepatol. 2023;29(4):891-908.   Published online April 13, 2023
View: 4429   Download: 1,107  Citation: 1
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clin Mol Hepatol. 2023;29(4):909-923.   Published online May 25, 2023
View: 1600   Download: 196  Citation: 1
1835
Evidence-based hyponatremia management in liver disease
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clin Mol Hepatol. 2023;29(4):924-944.   Published online June 5, 2023
View: 1791   Download: 182  Citations: 3
1844
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma
Hwa Kyung Byun, Changhwan Kim, Jinsil Seong
Clin Mol Hepatol. 2023;29(4):945-957.   Published online August 14, 2023
View: 1183   Download: 60  Citations: 2
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma
Sung Uk Lee, Tae Hyun Kim
Clin Mol Hepatol. 2023;29(4):958-968.   Published online August 29, 2023
View: 1077   Download: 55  Citation: 1
Editorial
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
Ming-Lun Yeh, Ming-Lung Yu
Clin Mol Hepatol. 2023;29(4):969-972.   Published online September 18, 2023
View: 927   Download: 111
Adding to the confusion in more than just the name
Jacob George
Clin Mol Hepatol. 2023;29(4):973-976.   Published online September 18, 2023
View: 739   Download: 42
Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy
Sang Min Yoon
Clin Mol Hepatol. 2023;29(4):977-979.   Published online August 31, 2023
View: 577   Download: 33
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
Eugene Han, Yong-ho Lee
Clin Mol Hepatol. 2023;29(4):980-983.   Published online August 16, 2023
View: 820   Download: 62
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?
Hyo-Cheol Kim
Clin Mol Hepatol. 2023;29(4):984-986.   Published online August 14, 2023
View: 817   Download: 25
Original Article
1838
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
Clin Mol Hepatol. 2023;29(4):987-1001.   Published online July 5, 2023
View: 1983   Download: 196  Citations: 4
1855
Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study
Vy H. Nguyen, Isaac Le, Audrey Ha, Richard Hieu Le, Nicholas Ajit Rouillard, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2023;29(4):1002-1012.   Published online September 11, 2023
View: 1200   Download: 71
1839
Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim
Clin Mol Hepatol. 2023;29(4):1013-1028.   Published online July 5, 2023
View: 1536   Download: 94  Citation: 1
1850
Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection
Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon
Clin Mol Hepatol. 2023;29(4):1029-1042.   Published online August 29, 2023
View: 1163   Download: 64
Letter to the Editor
1840
Letter regarding “Evidence-based hyponatremia management in liver disease”
Daphne J. Theodorou, Stavroula J. Theodorou, Ioannis V. Mitselos
Clin Mol Hepatol. 2023;29(4):1043-1045.   Published online July 5, 2023
View: 874   Download: 27  Citation: 1
Letter regarding “Risk factors in nonalcoholic fatty liver disease”
Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh
Clin Mol Hepatol. 2023;29(4):1046-1047.   Published online August 22, 2023
View: 768   Download: 29  Citation: 1
Correspondence
Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clin Mol Hepatol. 2023;29(4):1048-1049.   Published online August 14, 2023
View: 946   Download: 24
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”
Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(4):1050-1051.   Published online August 29, 2023
View: 660   Download: 20
Snapshot
1843
The role of the hepatic autonomic nervous system
Qiankun Luo, Pan Liu, Yifei Dong, Tao Qin
Clin Mol Hepatol. 2023;29(4):1052-1055.   Published online July 25, 2023
View: 849   Download: 40

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
CURRENT ISSUE
FOR CONTRIBUTORS
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 951
TOTAL : 1556129
Close layer